Literature DB >> 10537364

X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.

N Sawada1, T Ishikawa, F Sekiguchi, Y Tanaka, H Ishitsuka.   

Abstract

Thymidine phosphorylase (dThdPase) is an essential enzyme for the activation of the cytostatics capecitabine (N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) and its intermediate metabolite 5'-deoxy-5-fluorouridine (5'-dFUrd) to 5-fluorouracil (5-FUra) in tumors. We observed previously that several cytokines and cytostatics up-regulated dThdPase expression and consequently enhanced the efficacy of capecitabine and 5'-dFUrd. In the present study, we found that X-ray irradiation also up-regulated dThdPase expression in several human cancer xenografts. A single-dose local irradiation at 5 Gy increased dThdPase levels by up to 13-fold at 9 days after the irradiation. Whole-body irradiation also up-regulated dThdPase in a tumor, but it did not increase the enzyme level in the liver. We also observed that the irradiation increased the levels of human tumor necrosis factor alpha (TNF-alpha), which is an up-regulator of dThdPase, prior to the dThdPase up-regulation. These results indicate that X-ray irradiation might increase dThdPase levels indirectly through the human TNF-alpha in the tumor tissue. In the WiDr colon and MX-1 mammary human cancer xenograft models, the combination of a single local X-ray irradiation with either capecitabine or 5'-dFUrd was much more effective than either radiation or chemotherapy alone. In contrast, treatment with X-ray irradiation and 5-FUra in combination showed no clear additive effects. Combined modality treatment of cancer patients with cape-citabine and X-ray irradiation would have greater potential usefulness than conventional radiochemotherapy with 5-FUra.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537364

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

1.  Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer.

Authors:  Hisako Hirowatari; Kumiko Karasawa; Hiromi Izawa; Kana Ito; Keisuke Sasai; Tomohisa Furuya; Shuichi Ozawa; Atsushi Arakawa; Gotaro Orihata; Mitsue Saito
Journal:  Jpn J Radiol       Date:  2011-04-26       Impact factor: 2.374

2.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

3.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

4.  Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.

Authors:  L Vormittag; C Lemaire; D Radonjic; G Kornek; E Selzer
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

5.  Chemoradiotherapy for esophageal cancer.

Authors:  Geoffrey Neuner; Ashish Patel; Mohan Suntharalingam
Journal:  Gastrointest Cancer Res       Date:  2009-03

6.  Can the sequencing of concurrent capecitabine and radiation therapy improve the therapeutic ratio in rectal cancer?

Authors:  Gary Y Yang; Charles R Thomas
Journal:  Gastrointest Cancer Res       Date:  2007-03

7.  EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.

Authors:  A Sebio; J Salazar; D Páez; A Berenguer-Llergo; E Del Río; M Tobeña; M Martín-Richard; I Sullivan; E Targarona; J Balart; M Baiget; A Barnadas
Journal:  Pharmacogenomics J       Date:  2014-07-15       Impact factor: 3.550

Review 8.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

9.  Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.

Authors:  Jae Sung Kim; Jun Sang Kim; Moon June Cho; Wan Hee Yoon; Kye Sang Song
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

10.  A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.

Authors:  S Y K Ngan; M Michael; J Mackay; J McKendrick; T Leong; D Lim Joon; J R Zalcberg
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.